A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
a study on Cirrhosis Fibrosis Ascites Hepatorenal Syndrome Acute Kidney Injury
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.
The study aims are to evaluate the safety and efficacy of OCE-205 at various doses.
Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.
Official Title
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)
Details
The study will include 5 treatment arms including 1 Placebo Arm and 4 active drug arms. Participants will be randomly selected to 1 of 5 arms.
- Placebo
- OCE-205 at 8 micrograms per hour (µg/hr)
- OCE-205 at 15 micrograms per hour (µg/hr)
- OCE-205 at 30 micrograms per hour (µg/hr)
- OCE-205 at 50 micrograms per hour (µg/hr)
This multi-center trial will be conducted in the United States and Canada. If selected for the study, participants will be randomly assigned to 1 of the 5 treatment arms.
Keywords
Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury, HRS-AKI, Liver Cirrhosis, Syndrome, Fibrosis, Wounds and Injuries, OCE-205
Eligibility
You can join if…
Open to people ages 18-75
- Signed informed consent form (ICF) by participant or their legal/authorized representatives.
- Diagnosed with decompensated cirrhosis with ascites.
- Receiving albumin and has had appropriate diuretic withdrawal for at least 2 days prior to randomization into the study.
- Beta-blockers should be discontinued 48 hours prior to randomization, unless doctor deems necessary for appropriate medical treatment.
- No sustained improvement in renal function after both diuretic withdrawal and plasma volume expansion with albumin.
- Female participants must have a negative pregnancy test prior to randomization and agree to avoid becoming pregnant during the study and for 30 days after the end of treatment. Male participants must agree to use 2 effective contraceptive methods during the study and up to 30 days after the end of treatment.
You CAN'T join if...
- Serum Creatinine >3.8 mg/dL.
- Large volume paracentesis (LVP ≥6L) within 4 days of randomization.
- Pulse oximeter reading of <90% on 2L or less.
- Sepsis and/or uncontrolled bacterial infection.
- Experienced shock within 72 hrs prior to screening.
- Model for End-Stage Liver Disease (MELD) score >35.
- Hypertension with a Systolic BP > 140 mmHg and/ or a Diastolic BP >100 mmHg.
- Treated with or exposed to nephrotoxic agents or has had exposure to radiographic contrast agents within 72 hrs prior to screening.
- Has superimposed acute liver injury due to drugs, or toxins except for acute alcoholic hepatitis.
- Proteinuria greater than 500 mg/dL.
- Impaired cardiac function as evidenced by symptoms consistent with New York Heart Association Classification Class 2 or worse.
- Received Renal Replacement Therapy (RRT) within 4 weeks of randomization.
- Has had a Trans Jugular Intrahepatic Porto-systemic shunt (TIPS).
- Pregnant or breastfeeding.
- Diagnosed with a malignancy within the past 5 years.
- History or current evidence of any condition (COVID-19 positive with respiratory/cardiac complications), therapy or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest to participate in the opinion of the investigator.
- Participated in a study of an investigational medical product or device within the last 8 weeks preceding screening.
- Experienced a major blood loss (≥500 mL) within the last 4 weeks prior to screening.
- Is stuporous or comatose at screening (West Haven scores III and IV). exhibiting bradycardia.
Locations
- UCSF Liver Clinic
accepting new patients
San Francisco California 94143 United States - Keck Medical Center of USC
accepting new patients
Los Angeles California 90033 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ocelot Bio, Inc
- ID
- NCT05309200
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 100 study participants
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT05309200.